Status and Prospects for Psychopharmacology
Modern psychopharmacology has been evolving since the 1950s. Its contributions have been enormous and of fundamental importance to modern psychiatric therapeutics, encouraging and enabling the shift away from long-term institutional care, to brief inpatient interventions for crises, and reliance on ambulatory care. In addition, the clinical benefits provided by much of psychiatric chemotherapy, though typically incomplete, have stimulated decades of renewed efforts to develop a more biomedically based theoretical and academic psychiatry. In addition, the psychopharmaceutical industry has been especially successful in blending science and business to provide products of considerable social value.
KeywordsPsychiatric Disorder Psychotropic Drug Academic Psychiatry Abrupt Discontinuation Psychotropic Medicine
- 2.Angell M. The truth about the drug companies. New York: Random House; 2004.Google Scholar
- 3.Baldessarini RJ. American biological psychiatry and psychopharmacology 1944–1994, Chap. 16. In: Menninger RW, Nemiah JC, editors. American Psychiatry After World War II (1944–1994), a Volume Celebrating the 150th Anniversary of the Founding of the American Psychiatric Association. Washington DC: APA Press; 2000. p. 371–412.Google Scholar
- 9.Eliot TS. The Rock. London: Faber & Faber Publishers; 1934.Google Scholar
- 12.Harris G. Deal in place for inspecting foreign drugs. New York: New York Times; 13 August 2011. http://www.nytimes.com/2011/08/13/science/13drug.html?scp=2&sq=Gardiner%20Harris&st=cse.
- 13.Healy D. The Creation of Psychopharmacology. Cambridge, MA: Harvard University; 2002.Google Scholar
- 16.Lazare A, editor. Outpatient Psychiatry: Diagnosis and Treatment. 2nd ed. Philadelphia, PA: Lippincott-Williams & Wilkins; 1988.Google Scholar
- 18.Lieberman JA. Psychiatric drug development: why so slow? 2010. http://www.medscape.com/viewarticle/721671.
- 20.Marron DB, editor. Research and development in the pharmaceutical industry. Washington, DC: Congressional Budget Office (SBO) of the US; 2006. 65pp. http://www.google.com/search?client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&channel=s&hl=en&gs_sm=s&gs_upl=3381l6036l0l9127l16l16l0l8l8l0l148l789l6.2l8l0&q=drug%20development%20research&ct=broad-revision&cd=4&ie=UTF-8&sa=X.
- 21.Meyers M. Happy accidents: serendipity in modern medical breakthroughs. New York: Arcade Publishers; 2007.Google Scholar
- 24.Payne K, Gurwitz D, editors. The economics of drug discovery and development. Drug Dev Res. 2010;71(special issue):445–506.Google Scholar
- 26.Rosen S, Baldessarini RJ. Acquisition costs of psychopharmacological agents (internal report). Belmont, MA: McLean Hospital Pharmacy Department; 2011.Google Scholar
- 35.World Health Organization. International Classification of Diseases, tenth revision (ICD-10). Geneva: World Health Organization (WHO) 1994.Google Scholar